Editor’s Note: This article originally appeared on Abbott’s website. Abbott announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical ...

Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers actionable and personalized meal guidance 3 to support in-the-moment decisions.

Some of medtech's most innovative technologies were on display at the Consumer Electronics Show (CES) in Las Vegas this week.

Diabetes remains a serious chronic disease worldwide, affecting approximately 589 million people 3 and often accompanied by cardiovascular complications. 4 People with Type 1 and Type 2 diabetes are 2 ...

Abbott made one of the biggest deals in recent medtech history last week when it announced its plan to acquire Exact Sciences — maker of colon cancer screening test Cologuard — for $23 billion.

Global healthcare company Abbott is collaborating with MATTER, the Chicago-based healthcare incubator, to advance innovation in healthcare. Abbott joins seven other healthcare organizations as a ...

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and ...

ABBOTT PARK, Ill., Oct. 28, 2022 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, named Abbott's FreeStyle Libre ® continuous ...

Abbott and Bigfoot Biomedical have entered into an agreement to develop and commercialize diabetes management systems, integrating Abbott's FreeStyle Libre glucose sensing technology with Bigfoot's ...

Abbott’s (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in every province across ...